Potential Immunotherapy against SARS-CoV-2: Strategy and Status

Abid    H.    Banday; Shameem    A.    Shah; Sheikh    J.    Ajaz

doi:10.2174/2666796701999200625212040

Abstract

SARS-CoV-2, the novel coronavirus that was first reported in Wuhan, China in December 2019, has engrossed the world with immense distress. It has shattered the global healthcare system and has inflicted so much pain on humanity. COVID-19, the disease caused by a microscopic enemy, has now spread to almost all the countries in the world affecting millions of people and causing enormous casualties. World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2019. As of June 15, 2020, almost 7.70 million people have already been infected globally with 428,000 reported casualties. In the United States alone, 2.14 million people have been infected and 117,000 people have succumbed to this pandemic. A multipronged approach has been launched towards combating this pandemic with the main focus on exhaustive screening, developing efficacious therapies, and vaccines for long-term immunity. Several pharmaceutical companies in collaboration with various academic institutions and governmental organizations have started investigating new therapeutics and repurposing approved drugs so as to find fast and affordable treatments against this disease. The present communication aims at highlighting the efforts that are currently underway to treat or prevent SARS-CoV-2 infection through immunotherapy. Emphasis has been laid on discussing the approaches and platforms that are being utilized for the speedy development of therapeutic antibodies and preventive vaccines against SARS-CoV-2. The manuscript also presents a detailed discussion regarding strategy, clinical status, and timeline for the development of safe and enduring immunotherapy against SARS-CoV-2. All the details pertaining to the clinical status of each candidate have been last updated on June 15, 2020.

Keywords: COVID-19, SARS-CoV-2, ACE2 receptors, immunotherapy, monoclonal antibodies, Vaccines.

[1] 
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020; 26(4): 450-2.
[http://dx.doi.org/10.1038/s41591-020-0820-9] [PMID: 32284615] 
[2] 
Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis  2020; 4: 1-7.
[PMID:  32333222] 
[3] 
Boni MF, Lemey P, Jiang X, et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. bioRxiv 2020.
[4] 
Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report.
Immunity 2020; 52(4): 583-9 
[http://dx.doi.org/10.1016/j.immuni.2020.03.007] [PMID: 32259480] 
[5] 
Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of
SARS-CoV-2 on virus entry and its immune cross-reactivity with
SARS-CoV. Nat Commun 2020; 11(1): 1620 
[http://dx.doi.org/10.1038/s41467-020-15562-9] [PMID: 32221306] 
[6] 
Bombardini T, Picano E. Angiotensin-Converting Enzyme 2 as the
molecular bridge between epidemiologic and clinical features of
COVID-19. Can J Cardiol 2020; 36(5): 784.e1-2 
[http://dx.doi.org/10.1016/j.cjca.2020.03.026] [PMID: 32299780] 
[7] 
Xia H, Lazartigues E. Angiotensin-converting enzyme 2 in the
brain: properties and future directions. J Neurochem 2008; 107(6):
1482-94. 
[http://dx.doi.org/10.1111/j.1471-4159.2008.05723.x] [PMID: 19014390] 
[8] 
Baig AM. Neurological manifestations in COVID-19 caused by
SARS-CoV-2. CNS Neurosci Ther 2020; 26(5): 499-501 
[http://dx.doi.org/10.1111/cns.13372] [PMID: 32266761] 
[9] 
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19
virus targeting the cns: tissue distribution, host-virus interaction,
and proposed neurotropic mechanisms. ACS Chem Neurosci 2020;
11(7): 995-8 
[http://dx.doi.org/10.1021/acschemneuro.0c00122] [PMID: 32167747] 
[10] 
Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry
occurs through the endo-/lysosomal pathway in a proteolysisdependent
manner. PLoS Pathog 2014; 10(11): e1004502 
[http://dx.doi.org/10.1371/journal.ppat.1004502] [PMID: 25375324] 
[11] 
 Modes of transmission of virus causing COVID-19: implications
for IPC precaution recommendations https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations
[12] 
Insight into Community Transmission of COVID-19. https://www.infectioncontroltoday.com/covid-19/insight-community-transmission-covid-19-note-hospitals-are-communities
[13] 
Symptoms of Coronavirus (COVID-19) https://www.cdc.gov/coronavirus/2019-ncov/downloads/COVID19-symptoms.pdf
[14] 
Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real
estimates of mortality following COVID-19 infection. Lancet Infect
Dis 2020; S1473-3099(20): 30195-X 
[http://dx.doi.org/10.1016/S1473-3099(20)30195-X] [PMID: 32171390] 
[15] 
Li Q, Guan X, Wu P, et al. Early Transmission dynamics in wuhan,
china, of novel coronavirus-infected pneumonia. N Engl J Med
2020; 382(13): 1199-207 
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857] 
[16] 
Naran K, Nundalall T, Chetty S, Barth S. Principles of
Immunotherapy: Implications for Treatment Strategies in Cancer
and Infectious Diseases. Front Microbiol 2018; 9: 3158-80. 
[http://dx.doi.org/10.3389/fmicb.2018.03158] [PMID: 30622524] 
[17] 
Seib KL, Dougan G, Rappuoli R. The key role of genomics in
modern vaccine and drug design for emerging infectious diseases.
PLoS Genet 2009; 5(10): e1000612 
[http://dx.doi.org/10.1371/journal.pgen.1000612] [PMID: 19855822] 
[18] 
Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein
of SARS-CoV--a target for vaccine and therapeutic development.
Nat Rev Microbiol 2009; 7(3): 226-36 
[http://dx.doi.org/10.1038/nrmicro2090] [PMID: 19198616] 
[19] 
Jiang S, He Y, Liu S. SARS vaccine development Emerg Infect
Dis 2005; 11(7): 1016-20.. 
[http://dx.doi.org/10.3201/1107.050219] [PMID: 16022774] 
[20] 
Gabriella, di.M.; Cristina, S.; Concetta, R.; Francesco, R.; Annalisa,
C. SARS-CoV-2 infection: Response of human immune system and
possible implications for the rapid test and treatment. Int
Immunopharmacol 2020; 84: 106519-21 
[http://dx.doi.org/10.1016/j.intimp.2020.106519] 
[21] 
People Who Are at Higher Risk for Severe Illness. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html
[22] 
In the race to develop a coronavirus treatment, regeneron thinks it
 has the inside track https://www.statnews.com/2020/02/05/in-the-race-to-develop-a-coronavirus-treatment-regeneron-thinks-it-has-the-inside-track/
[23] 
Kevzara (Sarilumab). A Novel IL-6 Receptor Antagonist for Rheumatoid Arthritis http://www.ahdbonline.com/supplements/2438-kevzara-sarilumab-a-novel-il-6-receptor-antagonist-for-rheumatoid-arthritis
[24] 
Lamb YN, Deeks ED. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis Drugs 2018; 78(9): 929-40. 
[http://dx.doi.org/10.1007/s40265-018-0929-z] [PMID: 29931592] 
[25] 
FDA Approves Sarilumab for Adults With Rheumatoid Arthritis https://www.medscape.com/viewarticle/880473
[26] 
EU approval for Regeneron and Sanofi’s rheumatoid arthritis drug https://www.europeanpharmaceuticalreview.com/news/62816/eu-approval-kevzara/
[27] 
Sanofi, Regeneron launch trials of arthritis drug Kevzara for
 COVID-19 http://www.pmlive.com/pharmanews/sanofi,regeneron
[28] 
Sanofi and Regeneron begin global Kevzara (sarilumab) clinical
trial program in patients with severe COVID-19 http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19
[29] 
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the
 2019-nCoV spike in the prefusion conformation.
  Science  2020; 367(6483): 1260-3.
[http://dx.doi.org/10.1126/science.abb2507] [PMID:  32075877] 
[30] 
Lan J, Ge J, Yu J, et al. Crystal structure of the 2019-nCoV spike
receptor-binding domain bound with the ACE2 receptor. bioRxiv
 2019. https://www.biorxiv.org/content/10.1101/2020.02.19.956235v1
[31] 
Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome Science 2003; 300(5624): 1394-9.. 
[http://dx.doi.org/10.1126/science.1085952] [PMID: 12730500] 
[32] 
Thiel V, Ivanov KA, Putics Á, et al. Mechanisms and enzymes
involved in SARS coronavirus genome expression. J Gen Virol
 2003; 84(Pt 9): 2305-15. 
[http://dx.doi.org/10.1099/vir.0.19424-0] [PMID: 12917450] 
[33] 
AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19. https://investor.lilly.com/news-releases/news-release-details/abcellera-and-lilly-co-develop-antibody-therapies-treatment2020
[34] 
Lilly to Start Testing Experimental Drug in Coronavirus Patients
 Soon  https://www.wsj.com/articles/lilly-to-start-testing-experimental-drug-in-coronavirus-patients-soon-11587660027
[35] 
Pharma chiefs expect coronavirus vaccine in 12-18 months https://www.dawn.com/news/1542367
[36] 
 Moderna, NIAID Partner on Planned Trial of Coronavirus mRNA Vaccine https://www.genengnews.com/news/moderna-niaid-partner-on-planned-trial-of-coronavirus-mrna-vaccine/
[37] 
Moderna Announces First Participant Dosed in NIH-led Phase 1
Study of mRNA Vaccine (mRNA-1273) Against Novel
 Coronavirus. https://www.businesswire.com/news/home/20200316005666/en/Moderna-Announces-Participant-Dosed-NIH-led-Phase-1
[38] 
Moderna starts dosing in Phase II Covid-19 vaccine trial https://wwwclinicaltrialsarenacom/news/moderna-phaseii-vaccinetrial
https://www.clinicaltrialsarena.com/news/moderna-phaseiivaccine-
trial/
[39] 
COVID-19 vaccine tracker https://wwwrapsorg/news-andarticles/
news-articles/2020/3/covid-19-vaccine-tracker
https://www.raps.org/news-and-articles/news-articles/2020/3/covid-
19-vaccine-tracker
[40] 
INOVIO. Initiates. Phase 1 Clinical Trial Of Its COVID-19 Vaccine
and Plans First Dose Today http://ir.inovio.com/news-and-media/news/press-release-details/2020/INOVIO-Initiates-Phase-1-Clinical-Trial-Of-Its-COVID-19-Vaccine-and-Plans-First-Dose-Today/default.aspx
[41] 
A second potential COVID-19 vaccine, backed by Bill and Melinda
Gates, is entering human testing https://techcrunch.com/2020/04/06/a-second-potential-covid-19-vaccine-backed-by-bill-and-melinda-gates-is-entering-human-testing/
[42] 
Pfizer, BioNTech to co-develop potential coronavirus vaccine https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pfizer-biontech-to-co-develop-potential-coronavirus-vaccine/articleshow/74668162.cms?from=mdr
[43] 
Pfizer and BioNTech announce further details on collaboration to
accelerate global covid-19 vaccine https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration
[44] 
BioNTech and Pfizer announce completion of dosing for first
cohort of phase 1/2 trial of covid-19 vaccine candidates in Germany https://investors.pfizer.com/investor-news/press-release-details/2020/BioNTech-and-Pfizer-announce-completion-of-dosing-for-first-cohort-of-Phase-1-2-trial-of-COVID-19-vaccine-candidates-in-Germany/default.aspx
[45] 
BioNTech in China alliance with Fosun over potential coronavirus
vaccine https://in.reuters.com/article/us-biontech-fosunpharma-vaccine-collabor/biontech-in-china-alliance-with-fosun-over-potential-coronavirus-vaccine-idINKBN2130O5
[46] 
Arcturus Reports Positive Preclinical Data for its COVID-19
Vaccine Candidate https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-reports-positive-preclinical-data-its-covid-19-vaccine
[47] 
Arcturus Announces Summer COVID-19 Vaccine Trial http://sdbj.com/news/2020/apr/19/arcturus-announces-summer-covid-19-vaccine-trial/
[48] 
Biopharma Update on the Novel Coronavirus. https://www.biospace.com/article/biopharma-update-on-the-novel-coronavirus-april-9/
[49] 
Arcturus Therapeutics Announces Clinical Trial Timeline for its
COVID-19 Vaccine https://www.biospace.com/article/releases/arcturus-therapeutics-announces-clinical-trial-timeline-for-its-covid-19-vaccine/
[50] 
San Diego’s Arcturus Therapeutics will get up to $10M from
Singapore for coronavirus vaccine https://www.sandiegouniontribune.com/business/biotech/story/2020-03-05/arcturus-therapeutics-nets-up-to-10-million-in-funding-from-singapore-for-covid-19-vaccine
[51] 
About CureVac’s activities regarding an mRNA based vaccine
against COVID-19 https://www.curevac.com/covid-19#
[52] 
CureVac and CEPI extend their Cooperation to Develop a Vaccine
against Coronavirus nCoV-2019 https://centerforvaccineethicsandpolicy.net/2020/02/02/announcements-142/
[53] 
Is mRNA the Key to a Coronavirus Vaccine? https://www.fool.com/investing/2020/04/09/is-mrna-the-key-to-a-coronavirus-vaccine.aspx
[54] 
CureVac focuses on the development of mRNA-based coronavirus
vaccine to protect people worldwide https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide
[55] 
China's CanSino pushes coronavirus vaccine into clinical testing as
Moderna kicks off trial https://www.businesswire.com/news/home/20200316005666/en/Moderna-Announces-Participant-Dosed-NIH-led-Phase-1
[56] 
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for
COVID-19 (Adenovirus Vector) (CTII-nCoV) https://clinicaltrials.gov/ct2/show/NCT04341389
[57] 
Oxford COVID-19 vaccine to begin phase II/III human trials http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials
[58] 
Johnson Johnson Announces a Lead Vaccine Candidate for
COVID-19; Landmark New Partnership with US Department of
Health Human Services; and Commitment to Supply One Billion
Vaccines Worldwide for Emergency Pandemic Use https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use
[59] 
Johnson Johnson Announces Acceleration of its COVID-19
Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second
Half of July https://www.jnj.com/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate-phase-1-2a-clinical-trial-to-begin-in-second-half-of-july
[60] 
Johnson Johnson will have 600-800 million coronavirus vaccines
by 2021 2021. https://nypost.com/2020/04/15/johnson-johnson-eyes-600-million-coronavirus-vaccines-by-early-2021/
[61] 
Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine
[62] 
Sanofi and GSK to join forces in unprecedented vaccine
collaboration to fight COVID-19 https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00
[63] 
Sinovac says early data show its Covid-19 vaccine generated
immune responses https://www.statnews.com/2020/06/14/sinovac-early-data-covid19-vaccine-generated-immune-responses/
[64] 
Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine  2005; 23(24): 3210-22.
[http://dx.doi.org/10.1016/j.vaccine.2004.11.072] [PMID:  15837222] 

Rights & Permissions Print Cite

Article Metrics

10

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/2666796701999200625212040	Print ISSN 2666-7967
Publisher Name Bentham Science Publisher	Online ISSN 2666-7975

Coronaviruses

Potential Immunotherapy against SARS-CoV-2: Strategy and Status

Abstract Play Pause

Related Journals

Related Books

Related Articles

Abstract